Welcome to our dedicated page for BOUNDLESS BIO SEC filings (Ticker: BOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles SEC filings for Boundless Bio, Inc. (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology and ecDNA-directed therapeutics (ecDTx) for oncogene-amplified cancers. The filings provide official details on the company’s financial condition, governance, and key corporate events.
Among the documents available are Current Reports on Form 8-K. For example, Boundless Bio filed 8-Ks dated August 5, 2025, and November 5, 2025, each noting that the company issued press releases announcing financial results for the quarters ended June 30, 2025, and September 30, 2025, respectively. These 8-Ks explain that the earnings press releases are furnished as exhibits and describe how they are treated under Section 18 of the Securities Exchange Act of 1934.
An additional Form 8-K dated June 23, 2025, reports the results of the company’s annual meeting of stockholders. This filing summarizes stockholder votes on the election of Class I directors to serve until the 2028 annual meeting of stockholders and on the ratification of KPMG LLP as Boundless Bio’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Vote totals for each proposal are presented in tabular form within the filing.
In its press releases, Boundless Bio also directs readers to annual and quarterly reports, such as its Form 10-K for the year ended December 31, 2024, and its Form 10-Q for the quarter ended September 30, 2025, for detailed risk factor discussions and additional financial and operational information. Those filings, together with 8-Ks, form the core of the company’s SEC disclosure record.
On Stock Titan, these filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand items such as earnings announcements, stockholder vote outcomes, and updates referenced in 8-Ks. Real-time integration with the SEC’s EDGAR system means new BOLD filings appear promptly, while structured views make it easier to locate specific forms, including 8-Ks related to financial results and governance matters. This allows users to review Boundless Bio’s regulatory history and disclosures that frame the development of its ecDTx pipeline and clinical programs.
Boundless Bio (Nasdaq: BOLD) filed its Q3 report and posted a net loss of $13.9 million. Operating expenses were $15.1 million, driven by research and development of $10.7 million and general and administrative of $4.5 million. Interest income was $1.3 million.
Liquidity remained solid with $117.6 million in cash, cash equivalents, and short‑term investments as of September 30, 2025. Management states this supports operations into the first half of 2028. The company has an at‑the‑market equity program of up to $14.5 million; no shares were sold under the program as of September 30, 2025.
Pipeline updates center on the POTENTIATE study: the BBI‑355 (CHK1 inhibitor) and BBI‑825 (RNR inhibitor) combination arm opened for enrollment in Q3 2025. Earlier monotherapy and third‑party combo arms of BBI‑355 were wound down in May 2025 as part of a portfolio prioritization and cost streamlining. Beyond the lead program, the company selected BBI‑940 (Kinesin degrader) as a development candidate and expects to submit an IND and start first‑in‑human testing in the first half of 2026. Shares outstanding were 22,385,611 as of October 31, 2025.
Boundless Bio (BOLD) furnished an 8‑K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference. Consistent with General Instruction B.2, the information in this report, including Exhibit 99.1, is being furnished and not filed under the Exchange Act. The filing also lists the Cover Page Interactive Data File as Exhibit 104.
RA Capital and related reporting persons reported they do not beneficially own any shares of Boundless Bio, Inc. The Schedule 13G/A for CUSIP 10170A100 lists RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah and shows aggregate beneficial ownership of 0.00 shares representing 0.0% of the class as of June 30, 2025. Each reporting person also disclaims status as a "group." The filing states the securities were not acquired to influence control of the issuer and incorporates a Joint Filing Agreement by reference.
Overview: Boundless Bio (Nasdaq: BOLD) is a clinical-stage precision oncology company focused on ecDNA-directed therapeutics (ecDTx). The company reported no revenue and an accumulated deficit of $232.9 million as of June 30, 2025.
Key financials (as of/for June 30, 2025): Cash and cash equivalents of $14.7 million, short-term investments of $112.5 million (total cash, cash equivalents and short-term investments of $127.1 million). Net loss was $31.4 million for the six months ended June 30, 2025 and $15.7 million for the quarter ended June 30, 2025. Operating cash used was $26.4 million for the six months ended June 30, 2025.
Operational and program updates: Company completed portfolio prioritization May 23, 2025, discontinued certain single-agent arms of BBI-355 and halted escalation of BBI-825 dosing, opened a BBI-355/BBI-825 combination arm in the POTENTIATE trial, selected kinesin degrader development candidate BBI-940 with an expected IND submission in H1 2026, and implemented a workforce reduction of approximately one-third. Management expects existing cash, cash equivalents, and short-term investments to fund operations into the first half of 2028.
Boundless Bio director Christine Brennan received a stock option grant on June 23, 2025. Key details of the transaction:
- Granted 16,000 stock options to purchase common stock
- Exercise price set at $1.03 per share
- Options expire on June 22, 2035
- Vesting schedule: Equal monthly installments over 12 months through June 23, 2026
- Accelerated vesting provision if next annual stockholder meeting occurs before June 23, 2026
The grant was executed under direct ownership, and the filing was signed by Jessica Oien as attorney-in-fact for Christine Brennan. This equity compensation aligns with standard director compensation practices and aims to align the director's interests with shareholders.
Boundless Bio, Inc. (NASDAQ: BOLD) filed a Form 4 disclosing that director James Christensen received a new stock-option grant on 06/23/2025. The award covers 16,000 options with an exercise price of $1.03 per common share and an expiration date of 06/22/2035. The option vests in substantially equal monthly installments over the 12 months following the grant date. Any unvested portion will accelerate and vest on the date of the company’s next annual shareholder meeting if that meeting occurs before 06/23/2026, provided the director remains on the board.
The filing shows that these options represent the entirety of Christensen’s reported derivative holdings after the transaction; no open-market purchases, sales, or other equity awards were reported. Ownership is listed as direct, indicating the director personally holds the options rather than through a trust or other entity. No non-derivative (common-stock) transactions were disclosed.
Because the filing reports a routine board compensation grant rather than a discretionary insider purchase or sale, it is typically regarded as a neutral governance event for valuation purposes. There is no accompanying financial guidance, earnings data, or indication of broader corporate actions.
Director Jennifer Lew of Boundless Bio received a stock option grant on June 23, 2025. The grant consists of options to purchase 16,000 shares of common stock at an exercise price of $1.03 per share.
Key details of the stock option grant:
- Exercise price: $1.03 per share
- Expiration date: June 22, 2035
- Vesting schedule: Monthly installments over 12 months through June 23, 2026
- Accelerated vesting provision: Any unvested portion will vest at next annual stockholder meeting if occurring before June 23, 2026
- Vesting contingent on continued board service
The Form 4 was filed by Jessica Oien as attorney-in-fact for Jennifer Lew, reporting a direct ownership form of the derivative securities.
Director Jonathan E. Lim of Boundless Bio received a stock option grant on June 23, 2025, representing a significant insider transaction. The key details include:
- Granted 24,000 stock options to purchase common stock
- Exercise price set at $1.03 per share
- Options expire on June 22, 2035
- Vesting schedule: Equal monthly installments over 12 months through June 23, 2026
- Accelerated vesting provision if next annual stockholder meeting occurs before June 23, 2026
The grant was executed under direct ownership, with Jessica Oien signing as attorney-in-fact. This equity compensation aligns with standard director compensation practices and demonstrates the company's commitment to retaining board talent through long-term incentives.
Form 4 Overview: On 06/23/2025, Boundless Bio, Inc. (ticker BOLD) filed a Form 4 disclosing a grant of derivative securities to director and 10% owner Kristina Burow.
- Security granted: Stock option (right to buy)
- Quantity: 16,000 options
- Exercise price: $1.03 per share
- Vesting schedule: Monthly over 12 months beginning 06/23/2025; any unvested portion accelerates to the next annual shareholder meeting if earlier.
- Expiration: 06/22/2035
- Ownership form after transaction: Direct (16,000 derivative securities)
No non-derivative share transactions were reported. The filing represents routine director compensation rather than an open-market purchase, and it does not include financial performance metrics or earnings data.
FAQ
What is the current stock price of BOUNDLESS BIO (BOLD)?
What is the market cap of BOUNDLESS BIO (BOLD)?
